RE:RE:RE:RE:What am I missing.I questioned Pierre on OQP Korea's determination to spin out the biotechnology
business ( immunotherapy assets) into a separate company and pursue a public listing on a different exchange, and that OQP has not traded since March 2021, this was his response:
"Sure – because OQP has not traded since March 23, 2021, OQP is looking for a way to have trading re-established for its shares. The plan is to apply for a listing for the OQP shares on the KOTC Market in Korea. This market has reduced listing requirements compared to the KOSDAQ Market and is better suited for a research and development company, like OQP, that is not expected to generate revenue for a number of years.
Once the shares are listed for trading, OQP will be able to issue new shares to the public for cash in order to pay for the clinical trials. The hope is that the clinical trials will be successful, leading to product commercialization and revenue generation for OQP."
This deal with OQP seems to have many twists and turns.
G1945V